Key result
Novel oral anticoagulants provide effective stroke prophylaxis for patients with atrial fibrillation, overcoming many limitations of traditional vitamin K antagonists.
Why the study?
Do novel oral anticoagulants prevent stroke and systemic embolism in patients with atrial fibrillation compared to vitamin K antagonists?
Population
Patients with atrial fibrillation (specifically nonvalvular AF)
Comparison
Novel oral anticoagulants vs Vitamin K antagonists (warfarin)
Design
Review
Authors
Loading...
May support NOAC preference in nonvalvular AF; leaves open optimal use in underrepresented subgroups.
Do novel oral anticoagulants prevent stroke and systemic embolism in patients with atrial fibrillation compared to vitamin K antagonists?
Novel oral anticoagulants offer a convenient and effective alternative to vitamin K antagonists for stroke prevention in patients with nonvalvular atrial fibrillation.
Jacob I. Haft (2012) conducted a review in Atrial fibrillation. Novel oral anticoagulants vs. Vitamin K antagonists was evaluated on Stroke and systemic embolism. Novel oral anticoagulants provide effective stroke prophylaxis for patients with atrial fibrillation, overcoming many limitations of traditional vitamin K antagonists.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: